D. E. Shaw & Co., Inc. Viking Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 65,000 shares of VKTX stock, worth $4.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

65,000

Previous 75,742 14.18%

Holding current value

$4.48 Million

Previous $6.21 Million 44.52%

% of portfolio

0.0%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$47.39 - $80.2 $21.3 Million - $36.1 Million	449,760 Added 593.81%	525,502 $27.9 Million
Q1 2024 May 15, 2024	SELL	$17.4 - $94.5 $694,138 - $3.77 Million	-39,893 Reduced 34.5%	75,742 $6.21 Million
Q4 2023 Feb 14, 2024	BUY	$9.24 - $19.64 $274,012 - $582,424	29,655 Added 34.49%	115,635 $2.15 Million
Q3 2023 Nov 14, 2023	SELL	$10.92 - $16.0 $2.67 Million - $3.92 Million	-244,942 Reduced 74.02%	85,980 $951,000
Q2 2023 Aug 14, 2023	SELL	$14.84 - $24.79 $7.7 Million - $12.9 Million	-519,133 Reduced 61.07%	330,922 $5.36 Million
Q1 2023 May 15, 2023	SELL	$8.08 - $17.33 $817,574 - $1.75 Million	-101,185 Reduced 10.64%	850,055 $14.2 Million
Q4 2022 Feb 14, 2023	BUY	$2.72 - $9.4 $2.55 Million - $8.81 Million	937,374 Added 6760.23%	951,240 $8.94 Million
Q3 2022 Nov 14, 2022	SELL	$2.55 - $3.89 $8,756 - $13,358	-3,434 Reduced 19.85%	13,866 $38,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $3.15 $335,443 - $500,780	-158,978 Reduced 90.19%	17,300 $50,000
Q1 2022 May 16, 2022	BUY	$3.0 - $4.88 $528,834 - $860,236	176,278 New	176,278 $529,000
Q3 2021 Nov 15, 2021	SELL	$5.58 - $7.04 $90,803 - $114,561	-16,273 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$5.19 - $6.73 $15,393 - $19,961	-2,966 Reduced 15.42%	16,273 $97,000
Q1 2021 May 17, 2021	SELL	$5.74 - $9.67 $31,719 - $53,436	-5,526 Reduced 22.31%	19,239 $122,000
Q4 2020 Feb 16, 2021	SELL	$5.3 - $6.71 $182,807 - $231,441	-34,492 Reduced 58.21%	24,765 $139,000
Q3 2020 Nov 16, 2020	SELL	$5.73 - $8.11 $87,439 - $123,758	-15,260 Reduced 20.48%	59,257 $345,000
Q2 2020 Aug 14, 2020	BUY	$4.35 - $8.08 $16,177 - $30,049	3,719 Added 5.25%	74,517 $537,000
Q1 2020 May 15, 2020	BUY	$3.45 - $7.95 $197,536 - $455,193	57,257 Added 422.84%	70,798 $331,000
Q4 2019 Feb 14, 2020	BUY	$6.38 - $8.73 $86,391 - $118,212	13,541 New	13,541 $109,000
Q4 2018 Feb 14, 2019	SELL	$7.16 - $16.21 $196,370 - $444,575	-27,426 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$9.7 - $19.65 $721,874 - $1.46 Million	-74,420 Reduced 73.07%	27,426 $478,000
Q2 2018 Aug 14, 2018	BUY	$3.88 - $12.74 $395,162 - $1.3 Million	101,846 New	101,846 $967,000

Others Institutions Holding VKTX

# of Institutions

478

Shares Held

66.1M

Call Options Held

6.24M

Put Options Held

3.01M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.28B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account